Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02212106 · ClinicalTrials.gov registry record · Phase 4
A Study to Evaluate the Safety and Tolerability of Trivalent Influenza Virus Vaccine in Children Aged 5 Years to < 9 Years
A Phase 4 study of Influenza, Human, sponsored by Seqirus.
- Completed
- Registry status
- Phase 4
- Development phase
- 402
- Enrollment target
- 11
- Study locations
NCT02212106 is a Phase 4 study of Influenza, Human that has completed, run by Seqirus. The registered enrollment target is 402 participants, below the 16,201-participant average among 18 other Influenza, Human trials with a reported enrollment target (98% lower). The trial reports 11 study locations across 7 states.
The verdict
NCT02212106, a Phase 4 study of Influenza, Human, has completed, sponsored by Seqirus.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 402 participants
- Enrollment target
- 11
- Study locations
Study Summary
This is a study to assess the safety of a bioCSL split virion, inactivated Trivalent Influenza Virus vaccine containing the 2014/2015 Northern Hemisphere strains of vaccine in children aged 5 years to less than 9 years. Comparison will be made to a licensed Quadrivalent Influenza Virus vaccine that complies with the FDA recommendations for the 2014/2015 influenza season in the US.
Conditions Studied
Interventions
- BIOLOGICAL bioCSL Trivalent Influenza Virus Vaccine (CSL TIV)
- BIOLOGICAL Comparator Quadrivalent Influenza Virus Vaccine
Study Locations (11)
North Carolina
- Site 290 - Durham
- Site 281 - Raleigh
- Site 280 - Winston-Salem
Texas
- Site 283 - Austin
- Site 282 - Fort Worth
- Site 288 - San Angelo
California
- Site 286 - Los Angeles
Idaho
- Site 289 - Boise
Missouri
- Site 287 - St Louis
New York
- Site 285 - Binghamton
South Carolina
- Site 284 - Charleston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 402 participants |
| Start Date | 2014-09 |
| Est. Completion | 2014-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02212106
The ClinicalTrials.gov registry entry for NCT02212106 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 402 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 16,201-participant average among 18 other Influenza, Human trials with a reported enrollment target (98% lower). The listed sponsor is Seqirus, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Influenza, Human appearing as the primary indexed condition, and to 2 interventions - of which bioCSL Trivalent Influenza Virus Vaccine (CSL TIV) is the first listed.
NCT02212106 reports 11 study locations spanning 7 distinct geographic areas - top geographies include North Carolina, Texas, California.
Frequently Asked Questions
What is clinical trial NCT02212106 about?
NCT02212106 is a clinical study titled "A Study to Evaluate the Safety and Tolerability of Trivalent Influenza Virus Vaccine in Children Aged 5 Years to < 9 Years". This is a study to assess the safety of a bioCSL split virion, inactivated Trivalent Influenza Virus vaccine containing the 2014/2015 Northern Hemisphere strains of vaccine in children aged 5 years to less than 9 years. Comparison will be made to a licensed Quadrivalent Influenza Virus vaccine that ...
What is the current status of trial NCT02212106?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 402 participants. The study started on 2014-09. Estimated completion is 2014-12.
What conditions does trial NCT02212106 study?
This clinical trial studies the following conditions: Influenza, Human.
What interventions are being tested in trial NCT02212106?
The interventions under investigation include: bioCSL Trivalent Influenza Virus Vaccine (CSL TIV) (BIOLOGICAL), Comparator Quadrivalent Influenza Virus Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT02212106?
This trial is sponsored by Seqirus, which has 25 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02212106 being conducted?
This trial has 11 study locations across California, Idaho, Missouri, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Influenza, Human
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Characterization of Humoral and Cellular Immune Responses Elicited by Influenza Vaccination in Healthy Adults
RECRUITING · Phase 4
-
Immunologic Response to FluMist vs. Flucelvax
COMPLETED · Phase 4
-
A Study to Evaluate the Immune Response and Safety of an Influenza Vaccine in Adults 18 Years of Age and Above
RECRUITING · Phase 2
-
Flu Infection at UPHS
RECRUITING
-
A Study to Assess the Immune Response and Safety of a Vaccine Against Influenza in Adults 18 Years of Age and Older
ACTIVE NOT RECRUITING · Phase 2
-
A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.